GSDMD and glioblastoma: In the SRA PRJNA482620 glioblastoma (GBM) cohort (22), which includes 66 patients treated with standard therapy and PD-1 inhibitors (nivolumab or pembrolizumab), higher GSDMD expression was associated with poorer overall survival (HR = 3.0719, p = 0.032, Supplementary Figure 1).